1-7 of 7
Marie Wislez
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract PR005: Tepotinib + osimertinib in EGFR-mutant NSCLC with MET amplification following first-line osimertinib: INSIGHT 2 primary analysis

Xiuning Le, Tae Min Kim, Valentina Guarneri, Pei Jye Voon, Boon Khaw Lim, Jinji Yang, Marie Wislez, Cheng Huang, Chong Kim Liam, Julien Mazieres, Lye Mun Tho, Hidetoshi Hayashi, Nguyen Nhung, Puey Ling Chia, Fillippo De Marinis, Jo Raskin, Qinghua Zhou, Giovanna Finochhiaro, Daniel Tan, Sabine Brutlach, Aurora O'Brate, Svenja Adrian, Karin Berghoff, Barbara Ellers-Lenz, Niki Karachaliou, Yi-Long Wu
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): PR005.
https://doi.org/10.1158/1535-7163.TARG-23-PR005
Published: 01 December 2023
View article titled, Abstract PR005: Tepotinib + osimertinib in <em>EGFR</em>-mutant NSCLC with <em>MET</em> amplification following first-line osimertinib: INSIGHT 2 primary analysis
Journal Articles

High TUBB3 Expression, an Independent Prognostic Marker in Patients with Early Non–Small Cell Lung Cancer Treated by Preoperative Chemotherapy, Is Regulated by K-Ras Signaling Pathway

Guénaëlle Levallet, Emmanuel Bergot, Martine Antoine, Christian Creveuil, Adriana O. Santos, Michelle Beau-Faller, Florence de Fraipont, Elisabeth Brambilla, Jérôme Levallet, Franck Morin, Virginie Westeel, Marie Wislez, Elisabeth Quoix, Didier Debieuvre, Fatéméh Dubois, Isabelle Rouquette, Jean-Louis Pujol, Denis Moro-Sibilot, Jacques Camonis, Gérard Zalcman
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (5): 1203–1213.
https://doi.org/10.1158/1535-7163.MCT-11-0899
Published: 08 May 2012
View article titled, High TUBB3 Expression, an Independent Prognostic Marker in Patients with Early Non–Small Cell Lung Cancer Treated by Preoperative Chemotherapy, Is Regulated by K-Ras Signaling Pathway
Open the PDF for High TUBB3 Expression, an Independent Prognostic Marker in Patients with Early Non–Small Cell Lung Cancer Treated by Preoperative Chemotherapy, Is Regulated by K-Ras Signaling Pathway in another window
Includes: Supplementary data
Journal Articles

Abstract A15: Establishment and characterization of a new patient-derived non-small cell lung cancer xenograft panel for pharmacological assessment.

Ludmilla Deplater, Lamia Ouafi, Patricia de Cremoux, Olfa Chouchane-Mlik, Catherine Daniel, Leila Zemoura, Andre Nicolas, Marion Richardson, Jerome Couturier, Ahmed Dahmani, Dalila Labiod, Marie Wislez, Alain Chapelier, Alain Livartowski, Didier Decaudin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A15.
https://doi.org/10.1158/1535-7163.TARG-11-A15
Published: 12 November 2011
View article titled, Abstract A15: Establishment and characterization of a new patient-derived non-small cell lung cancer xenograft panel for pharmacological assessment.
Journal Articles

Abstract A205: Targeting caspase-9/PP2A interaction as a new antitumor strategy.

Fariba Nemati, Issam Arrouss, Fernando Roncal, Marie Wislez, Jeronimo Bravo, Angelita Rebollo, Didier Decaudin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A205.
https://doi.org/10.1158/1535-7163.TARG-11-A205
Published: 12 November 2011
View article titled, Abstract A205: Targeting caspase-9/PP2A interaction as a new antitumor strategy.
Journal Articles

Dependence on Phosphoinositide 3-Kinase and RAS-RAF Pathways Drive the Activity of RAF265, a Novel RAF/VEGFR2 Inhibitor, and RAD001 (Everolimus) in Combination

Pierre Mordant, Yohann Loriot, Céline Leteur, Julien Calderaro, Jean Bourhis, Marie Wislez, Jean-Charles Soria, Eric Deutsch
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (2): 358–368.
https://doi.org/10.1158/1535-7163.MCT-09-1014
Published: 09 February 2010
View article titled, Dependence on Phosphoinositide 3-Kinase and RAS-RAF Pathways Drive the Activity of RAF265, a Novel RAF/VEGFR2 Inhibitor, and RAD001 (Everolimus) in Combination
Open the PDF for Dependence on Phosphoinositide 3-Kinase and RAS-RAF Pathways Drive the Activity of RAF265, a Novel RAF/VEGFR2 Inhibitor, and RAD001 (Everolimus) in Combination in another window
Includes: Supplementary data
Journal Articles

A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras

Yanan Yang, Marie Wislez, Nobukazu Fujimoto, Ludmila Prudkin, Julie G. Izzo, Futoshi Uno, Lin Ji, Amy E. Hanna, Robert R. Langley, Diane Liu, Faye M. Johnson, Ignacio Wistuba, Jonathan M. Kurie
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2008) 7 (4): 952–960.
https://doi.org/10.1158/1535-7163.MCT-07-2045
Published: 15 April 2008
View article titled, A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant <em>K-ras</em>
Open the PDF for A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant <em>K-ras</em> in another window
Journal Articles

Angiogenesis in non-small cell lung cancer (NSCLC): Gender differences in tumor and circulating angiogenic factors

Emer Hanrahan, Ludmila Prudkin, Heather Yan Lin, Carmen Behrens, Erminia Massarelli, Matthew Herynk, Danny Du, Marie Wislez, Jonathan Kurie, Roy Herbst, J. Jack Lee, Ignacio Wistuba, John Heymach
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): A24.
Published: 01 November 2007
View article titled, Angiogenesis in non-small cell lung cancer (NSCLC): Gender differences in tumor and circulating angiogenic factors